谷氨酰胺成像:胶质瘤管理的新途径
综述阐述谷氨酰胺代谢在胶质瘤中的重要性,并汇总MRS、PET、SPECT及临床前荧光与质谱成像等无创评估脑内谷氨酰胺的技术现状,讨论将其纳入胶质瘤个体化管理的障碍。
要点
- 谷氨酰胺代谢异常与胶质瘤治疗抵抗和增殖相关,是潜在预后标志物和治疗靶点。
- MRS、PET、SPECT可用于无创评估脑内谷氨酰胺代谢,临床前方法包括荧光和质谱成像。
- 将谷氨酰胺成像纳入胶质瘤个体化管理前仍需克服多项障碍。
核心结论
- 谷氨酰胺通路是胶质瘤预后标志物和新治疗靶点的重要方向,但无创评估工具有限制约了其临床转化。
研究设计与样本
- 综述类文章,检索范围与纳入文献数量原文未报告,汇总MRS、PET、SPECT及临床前荧光与质谱成像技术。
临床应用与阅片要点
- 日常阅片可关注MRS、PET、SPECT对脑内谷氨酰胺代谢的无创评估价值,为胶质瘤管理提供代谢信息。
局限性
- 综述类文章,原文未报告系统检索策略与纳入文献数量,且无创评估谷氨酰胺代谢的临床工具仍有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The glutamine pathway is emerging as an important marker of cancer prognosis and a target for new treatments. In gliomas, the most common type of brain tumors, metabolic reprogramming leads to abnormal consumption of glutamine as an energy source, and increased glutamine concentrations are associated with treatment resistance and proliferation. A key challenge in the development of glutamine-based biomarkers and therapies is the limited number of in vivo tools to noninvasively assess local glutamine metabolism and monitor its changes. In this review, we describe the importance of glutamine metabolism in gliomas and review the current landscape of translational and emerging imaging techniques to measure glutamine in the brain. These techniques include MRS, PET, SPECT, and preclinical methods such as fluorescence and mass spectrometry imaging. Finally, we discuss the roadblocks that must be overcome before incorporating glutamine into a personalized approach for glioma management.
引用
- Ekici, Nye, Neill, et al. Glutamine Imaging: A New Avenue for Glioma Management. AJNR Am J Neuroradiol. 2021. PMID: 34737183. doi:10.3174/ajnr.A7333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。